THYROCARE2026-10-302026-10-30THYROCARE2026-10-302026-10-30PartiesOfTheAgreementDomain3THYROCARE2026-10-30PartiesOfTheAgreementDomain1THYROCARE2026-10-302026-10-30PartiesOfTheAgreementDomain4THYROCARE2026-10-30THYROCARE2026-10-302026-10-30PartiesOfTheAgreementDomain1THYROCARE2026-10-302026-10-30PartiesOfTheAgreementDomain2THYROCARE2026-10-30PartiesOfTheAgreementDomain4THYROCARE2026-10-30PartiesOfTheAgreementDomain2THYROCARE2026-10-30PartiesOfTheAgreementDomain3xbrli:sharesxbrli:pure

Intimation on Agreements


Thyrocare Technologies Limited

General Information

NSE Symbol*THYROCARE
Type of Announcement*New
Type of Agreement*Shareholder agreements
If Others, specify the type of the agreement
Disclosure on Stage of Agreement*Execution of agreement
Details of other stage of agreement
Agreements entered into by* Listed Entity
Details of Other agreements entered into by
Whether Event/Information disclosed is an Outcome of Board Meeting?No
Date of occurrence of event*30-10-2026
Time of occurrence of event*17:08:00
Whether the Listed Entity is party to the agreement?Yes
Date of initial announcement
Date of latest announcement
Remarks (website dissemination)
Date of Report30-10-2026

Execution of agreement

Brief details of the Agreement*Sale of the entire shareholding held by Thyrocare Technologies Limited ("the Company") in Nueclear Healthcare Limited ("NHL"), a material wholly owned subsidiary of the Company, comprising 1,11,11,000 (One Crore Eleven Lakh Eleven Thousand) equity shares, representing 100% of the issued, subscribed and paid-up equity share capital of NHL, to Trovera Healthcare Private Limited. Accordingly, the Company has entered into a Share Purchase Agreement dated October 30, 2026, among the Company, NHL, Trovera Healthcare Private Limited and Dr. Prince Surana, for sale of the entire shareholding held by the Company in NHL, to Trovera Healthcare Private Limited ("Trovera" or "Purchaser"). The consideration will comprise (i) 42,500 (Forty Two Thousand Five Hundred) Compulsorily Convertible Preference Shares ("CCPS") of Trovera, having a face value of Rs. 10/- each and issued at a premium of Rs. 13,990/- per CCPS, aggregating to Rs. 59,50,00,000/- (Rupees Fifty-Nine Crore Fifty Lakh only); and (ii) cash consideration of approximately Rs. 81,90,00,000/- (Rupees Eighty One Crore Ninety Lakh only), subject to adjustment upon determination of the working capital adjustment amount in accordance with the provisions of the SPA. The consideration will be received upon completion of the transaction in accordance with the terms of the SPA.
Date of Board / Committee Meeting approving the agreement21-09-2026
Whether proposed / executed agreement is in normal course of business*No
If No, provide reasonsThe Transaction is related to sale of wholly owned subsidiary
Impact of agreement on management and control of the listed entity*No such impact of agreement on management and control of the listed entity
Number of Parties to the agreement*4
Sr. No.Name(s) of parties / counter parties of the agreement*Nature of the parties of the Agreement*Shareholding, if any, in the entity with whom the agreement is executed*Number of SharesPercentage of shareholdingWhether, the parties to the Agreement are related to promoter / promoter group / associate / holding / subsidiary / group companies / Director / KMP and its relatives in any manner.*Nature of relationship
1Thyrocare Technologies LimitedParty entering into the agreement000.00%NoNueclear Healthcare Limited ("NHL"), a material wholly owned subsidiary of the Company
2Nueclear Healthcare LimitedParty entering into the agreement111111000100.00%Yes
3Trovera Healthcare Private LimitedParty entering into the agreement000.00%No
4Dr. Prince SuranaParty entering into the agreement000.00%No
Whether the transaction would fall within related party transactions?No
Whether the transaction is done at "arms length" basis
If No, provide details
Date on which agreement was entered*30-10-2026
Purpose of entering into the agreement*Sale of the entire shareholding held by Thyrocare Technologies Limited ("the Company") in Nueclear Healthcare Limited ("NHL"), a material wholly owned subsidiary of the Company, comprising 1,11,11,000 (One Crore Eleven Lakh Eleven Thousand) equity shares, representing 100% of the issued, subscribed and paid-up equity share capital of NHL, to Trovera Healthcare Private Limited. The consideration will comprise (i) 42,500 (Forty Two Thousand Five Hundred) Compulsorily Convertible Preference Shares ("CCPS") of Trovera, having a face value of Rs. 10/- each and issued at a premium of Rs. 13,990/- per CCPS, aggregating to Rs. 59,50,00,000/- (Rupees Fifty-Nine Crore Fifty Lakh only); and (ii) cash consideration of approximately Rs. 81,90,00,000/- (Rupees Eighty One Crore Ninety Lakh only), subject to adjustment upon determination of the working capital adjustment amount in accordance with the provisions of the SPA. The consideration will be received upon completion of the transaction in accordance with the terms of the SPA.
Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;*Key terms of the SPA: (a) The completion under the SPA is subject to customary conditions precedent. (b) Pursuant to transfer of shares of NHL by the Company, as contemplated under the SPA, NHL will become wholly owned subsidiary of the Purchaser. (c) The purchase consideration will be discharged by way of cash consideration and issuance of securities of the Purchaser, as per the SPA.
Whether there is any issuance / transfer of shares to the parties*No
Class of shares issued/transferred
Issue Price per share
Details and quantification of the restriction or liability imposed upon the listed entity*No restriction or liability imposed upon the listed entity
Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc;Nil. No such control is exercised by any of the parties over the Company, and neither of the parties has the right to nominate or appoint any director on the Board of Directors of the Company. Accordingly, no potential conflict of interest arises in this regard
Any other disclosure w.r.t. compliance of any SEBI Act, Regulation, Circular or provision
Any other informationNo shares are being issued by the Company to any of the parties. However, as part of the total consideration set out in the SPA, the Company will subscribe to 42,500 Compulsorily Convertible Preference Shares (CCPS) of Trovera, having a face value of Rs. 10/- each, issued at a premium of Rs. 13,990/- per CCPS.
Remarks (for Website dissemination)